Gevaert Olivier, De Moor Bart
Katholieke Universiteit Leuven, Department of Electrical Engineering ESAT-SCD-Sista, Kasteelpark Arenberg 10, 3001 Leuven, Belgium +32 16 328646 ; +32 16 32 ;
Expert Opin Med Diagn. 2009 Mar;3(2):157-65. doi: 10.1517/17530050802680172.
The use of DNA microarray technology to predict cancer outcome already has a history of almost a decade. Although many breakthroughs have been made, the promise of individualized therapy is still not fulfilled. In addition, new technologies are emerging that also show promise in outcome prediction of cancer patients.
The impact of DNA microarray and other 'omics' technologies on the outcome prediction of cancer patients was investigated. Whether integration of omics data results in better predictions was also examined.
DNA microarray technology was focused on as a starting point because this technology is considered to be the most mature technology from all omics technologies. Next, emerging technologies that may accomplish the same goals but have been less extensively studied are described.
Besides DNA microarray technology, other omics technologies have shown promise in predicting the cancer outcome or have potential to replace microarray technology in the near future. Moreover, it is shown that integration of multiple omics data can result in better predictions of cancer outcome; but, owing to the lack of comprehensive studies, validation studies are required to verify which omics has the most information and whether a combination of multiple omics data improves predictive performance.
利用DNA微阵列技术预测癌症预后已有近十年的历史。尽管已取得许多突破，但个性化治疗的前景仍未实现。此外，新技术不断涌现，在癌症患者预后预测方面也显示出前景。
研究DNA微阵列和其他“组学”技术对癌症患者预后预测的影响。还探讨了整合组学数据是否能带来更好的预测效果。
以DNA微阵列技术为出发点，因为该技术被认为是所有组学技术中最成熟的技术。接下来，描述了可能实现相同目标但研究较少的新兴技术。
除了DNA微阵列技术外，其他组学技术在预测癌症预后方面已显示出前景，或在不久的将来有潜力取代微阵列技术。此外，研究表明整合多个组学数据可更好地预测癌症预后；但是，由于缺乏全面研究，需要进行验证研究以核实哪种组学拥有最多信息，以及多个组学数据的组合是否能提高预测性能。
